Publications - Page 32 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension.

Guignabert C, Savale L, Boucly A, Thuillet R, Tu L, Ottaviani M, Rhodes CJ, De Groote P, Prévot G, Bergot E, Bourdin A, Howard LS, Fadel E, Beurnier A, Roche A, Jevnikar M, Jaïs X, Montani D, Wilkins MR, Sitbon O, Humbert M.

Circulation. 2023 Jun 13;147(24):1809-1822.
Hypertension pulmonaire (HTP)
Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.

Sanges S, Rice L, Tu L, Valenzi E, Cracowski JL, Montani D, Mantero JC, Ternynck C, Marot G, Bujor AM, Hachulla E, Launay D, Humbert M, Guignabert C, Lafyatis R.

Ann Rheum Dis. 2023 Mar;82(3):365-373.
Hypertension pulmonaire (HTP)
Pulmonary arterial hypertension

Boucly A, Gerges C, Savale L, Jaïs X, Jevnikar M, Montani D, Sitbon O, Humbert M

Presse Med. 2023 Jul 27:104168.
Hypertension pulmonaire (HTP)
Molecular Function and Contribution of TBX4 in Development and Disease.

Karolak JA, Welch CL, Mosimann C, Bzdęga K, West JD, Montani D, Eyries M, Mullen MP, Abman SH, Prapa M, Gräf S, Morrell NW, Hemnes AR, Perros F, Hamid R, Logan MPO, Whitsett J, Galambos C, Stankiewicz P, Chung WK, Austin ED.

Am J Respir Crit Care Med. 2023 Apr 1;207(7):855-864.
Hypertension pulmonaire (HTP)
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB.

Eur Respir J. 2023 Jan 6;61(1):2201347.
Hypertension pulmonaire (HTP)
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators.

N Engl J Med. 2023 Apr 20;388(16):1478-1490.
Pneumopathies interstitielles diffuses (PID)
Inverted direct allorecognition triggers early donor-specific antibody responses after transplantation.

Charmetant X, Chen CC, Hamada S, Goncalves D, Saison C, Rabeyrin M, Rabant M, Duong van Huyen JP, Koenig A, Mathias V, Barba T, Lacaille F, le Pavec J, Brugière O, Taupin JL, Chalabreysse L, Mornex JF, Couzi L, Graff-Dubois S, Jeger-Madiot R, Tran-Dinh A, Mordant P, Paidassi H, Defrance T, Morelon E, Badet L, Nicoletti A, Dubois V, Thaunat O.

Sci Transl Med. 2022 Sep 21;14(663):eabg1046.
Pneumopathies interstitielles diffuses (PID)
Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study.

Rivière A, Picard C, Berastegui C, Mora VM, Bunel V, Godinas L, Salvaterra E, Rossetti V, Savale L, Israel-Biet D, Demant X, Bermudez J, Meloni F, Jaksch P, Magnusson J, Beaumont L, Perch M, Mornex JF, Knoop C, Aubert JD, Hervier B, Nunes H, Humbert M, Gottlieb J, Uzunhan Y, Le Pavec J.

Am J Transplant. 2022 Dec;22(12):2990-3001.
Dilatation des bronches ou bronchectasies (non CF, non DCP)
[Updated indications and contraindications in 2022 for lung transplantation in France].

Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M.

Rev Mal Respir. 2022 Dec;39(10):855-872.
Pneumopathies interstitielles diffuses (PID)
Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.

Nathan SD, Behr J, Cottin V, Lancaster L, Smith P, Deng CQ, Pearce N, Bell H, Peterson L, Flaherty KR.

BMJ Open Respir Res. 2022 Jul;9(1):e001310.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension.

Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.

Pulmonary arterial hypertension

Molecular Function and Contribution of TBX4 in Development and Disease.

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Inverted direct allorecognition triggers early donor-specific antibody responses after transplantation.

Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study.

[Updated indications and contraindications in 2022 for lung transplantation in France].

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.